NTT Group to Launch Asia's First Smart City Proof of Concept Collaborating with Cyberview and Allo in Malaysia
29.1.2020 09:00:00 EET | Business Wire | Press release
As part of the Japanese Ministry of Internal Affairs and Communications’ FY 2019 project "Research on Smart City Model for Solving Social Problems in Malaysia", based on the smart city initiatives which has been started with the City of Las Vegas, United States, NTT Group (Nippon Telegraph and Telephone Corporation (Hereinafter, NTT), NTT Communications Corporation, NTT Ltd., InfoCom Research, Inc., NTT DATA Corporation, NTT COMWARE Corporation) will conduct Asia's one of the first Smart City Proof of Concept (PoC) in the Cyberjaya area of Malaysia from February 2020, in cooperation with local stakeholders. Through this PoC, NTT Group aims to establish a sustainable business model while verifying the possibility of solving social issues in Asia, utilizing the technologies and know-how accumulated in the smart city field in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005904/en/
(Graphic: Business Wire)
1. Background
In Asian countries where stable economic growth continues, various social issues associated with economic growth such as traffic jams and environmental problems have become apparent, and the expectations for ICT-based solutions to these issues are growing. Among Asian countries, Malaysia, a country that built up friendly and mutually beneficial bilateral relationship with Japan through the (Look East) policy advocated by the Prime Minister Mahathir bin Mohamad in 1981, is no exception. There are high expectations that Japanese companies will utilize technologies and know-how cultivated globally, to contribute to the resolution of social issues and the economic development of Malaysia.
Cyberjaya is a neighboring city of Kuala Lumpur, the capital of Malaysia, and has attracted many ICT companies as the nucleus of the Multimedia Super Corridor (MSC) which has been proposed during the administration of the 4th Prime Minister, Mahathir bin Mohamad (1990 - 1995). In addition, the 5G network, which was put into trial operation with nation’s first OpenLab being hosted there, has positioned Cyberjaya as a pioneer test area for the smart city concept in Malaysia.
Since the establishment of a group company (NTT MSC Sdn Bhd) in 1997, NTT Group has been active with investments and business development to contribute to the technological development of the country, and has built a strong relationship with local stakeholders over many years. At this time, the collaboration has been focused on solving social issues with ICT.
2. Overview of the PoC
Through field tests using the technology and know-how of smart city solutions which NTT Group has deployed with the City of Las Vegas, U.S.A. since 2018 (*), NTT Group aims to improve the living conditions of citizens and the sustainability of cities through smart cities using ICT, by studying the possibility of solving social problems in Malaysia and building sustainable business models, together with local stakeholders.
*(press release) About the smart city solutions available in Las Vegas, USA
https://www.ntt.co.jp/news2018/1812/181208a.html
(1) Features of Solutions Delivered During the Field Test
Malaysia is a motorized society with road congestion, automobile accidents and dangerous driving occurring on daily basis. This is one of the emerging social problems that a smart city can resolve by conducting data collection and utilization of vehicle information.
During the field test, based on the vehicle monitoring solution that has been provided in the City of Las Vegas since February 2019, NTT Group will customize and provide similar solution to support the needs of local stakeholders. Specifically, by installing cameras at the intersection with the highest traffic volume in Cyberjaya, and analyzing traffic volume and vehicle information, NTT Group aims to reduce traffic congestion, detect stolen vehicles, and support the creation of businesses in the neighborhood.
(2) Points to be verified through PoC
Based on the results of the field test above, the following will be verified through discussions with stakeholders.
1) Challenges and feasibility of smart city solutions deployed in Coty of Las Vegas in terms of system construction and operational aspects in Malaysia
2) Possibility of business model development using the technology (Application Examples: Public Safety, Smart Infrastructure, Commercial Use)
3) Possibility of deployment to ASEAN countries (Reflecting market trends, legal systems, and local stakeholders' needs)
(3) Period and Location of PoC
- Implementation period: February to March 2020
- Implementation location: Cyberjaya, Malaysia
(4) Role of each entity
|
NTT Group |
NTT |
Overall supervision and coordination among group companies |
|
NTT Communications |
Supervision of Ministry of Internal Affairs and Communications’ research projects, support for installation of Multi-Orchestrator |
|
|
NTT Ltd (NTT MSC) |
Stakeholders coordination, implementation of PoC and proposal to stakeholders |
|
|
InfoCom Research |
Implementation of surveys, preparing reports, and support of proposal to stakeholders |
|
|
NTT DATA |
Support for deployment and technical of smart city solutions in Las Vegas |
|
|
NTT COMWARE |
Multi-Orchestrator delivery and technical assistance |
|
|
Local Stakeholders |
Cyberview (Tech Hub Developer) |
Support for implementation of field test, stakeholder coordination, and business model development |
|
Allo (Infrastructure provider) |
Provision of infrastructure for field test (optical fiber) |
3. Future Deployment
Based on the results of the PoC, NTT Group will promote the deployment of smart city solutions to Cyberjaya and other cities in Malaysia, as well as to ASEAN countries, with the aim of improving people's living conditions, improving urban sustainability, and realizing a smart society.
About NTT
NTT is a Global Technology and Business Solutions Provider. We help clients accelerate growth and innovate new digital business models of the future. We provide business consulting and technology services for global networks, cybersecurity, managed IT and applications, workplace, datacenter and cloud services all supported by our deep industry expertise and innovation.
As a top five Global IT Services provider, our globally diverse and inclusive workforce supports clients in 80+ countries and regions. This includes 85% of the Fortune Global 100 companies and thousands of other clients and communities. With a 120-year heritage of service, innovation and social responsibility, we always advocate and act for our clients and a sustainable future. For more information on NTT, visit www.global.ntt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005904/en/
Contact information
Media Contacts
Nippon Telegraph and Telephone Corporation (NTT)
Public Relations Office
E-mail: ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
